Supernus Pharmaceuticals ( (SUPN) ) has released its Q4 earnings. Here is a breakdown of the information Supernus Pharmaceuticals presented to its investors.
Supernus Pharmaceuticals is a biopharmaceutical company that specializes in developing and commercializing treatments for central nervous system diseases, with a diverse portfolio that includes products for ADHD, Parkinson’s disease, epilepsy, and more.
In its latest earnings report, Supernus Pharmaceuticals announced a significant increase in net sales for its key products, Qelbree and GOCOVRI, for the fourth quarter and full year of 2024. The company also reported a strong improvement in operating earnings, transitioning from a loss in the previous year to substantial earnings in 2024.
The financial highlights reveal that Qelbree’s net sales surged by 60% in the fourth quarter and 72% for the full year, while GOCOVRI saw a 15% increase in the fourth quarter and a 9% rise for the year. Total revenues for 2024 grew by 9% to $661.8 million, with a notable 25% increase in revenues excluding certain products. The company also achieved a significant turnaround in operating earnings, reporting $81.7 million for 2024 compared to a loss in 2023.
Strategically, Supernus is preparing to launch ONAPGO, a new treatment for Parkinson’s disease, in the second quarter of 2025. The company is also advancing its product pipeline with ongoing studies for epilepsy and depression treatments, although some challenges remain, such as the lack of significant results in a recent depression study.
Looking ahead, Supernus Pharmaceuticals projects total revenues for 2025 to be between $600 million and $630 million, with adjusted operating earnings expected to range from $105 million to $130 million. The company is focused on sustaining the growth of its core products and successfully launching new treatments to enhance its market position.